Saillant Therapeutics
  • Home
  • Platform Technology
  • Company
  • News
  • Contact
Select Page

Persbericht: Saillant Therapeutics rapporteert proof of concept in de behandeling van hartfalen

Nov 4, 2020 | press release

Saillant Therapeutics meldt succes in preklinisch onderzoek bij de behandeling van hartfalen, met herstel van functie en zelfs regeneratie van de hartspier Nijmegen, 4 november, 2020 — Saillant Therapeutics, een biotechnologiebedrijf in de preklinische fase dat...

Press Release: Saillant Therapeutics reports proof of concept in heart failure treatment

Nov 4, 2020 | press release

Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure showing Functional Reversal and Myocardial Rejuvenation Nijmegen, The Netherlands, 4 November, 2020 — Saillant Therapeutics, an innovative preclinical stage biotechnology company...

Press Release: Saillant Therapeutics to develop generic virus inhibiting therapy

Aug 14, 2020 | press release

Dutch Saillant Therapeutics to develop generic virus inhibiting therapy based on activation of a cellular master regulator, ending virus replication Nijmegen, The Netherlands, 11 August 2020 — Saillant Therapeutics, an innovative biotechnology start-up,...

Recent Posts

  • Persbericht: Saillant Therapeutics rapporteert proof of concept in de behandeling van hartfalen
  • Press Release: Saillant Therapeutics reports proof of concept in heart failure treatment
  • Press Release: Saillant Therapeutics to develop generic virus inhibiting therapy

Recent Comments

    Navigation

    • Home
    • Platform Technology
    • Company
    • News
    • Contact

    Contact

    info@saillanttherapeutics.nl

    Transistorweg 7
    6534AT Nijmegen
    The Netherlands

    Saillant Therapeutics Logo
    • LinkedIn
    Copyright Saillant Therapeutics BV 2020-2023 | Designed and managed by Lyfsci.